Survival Improvements in Ovarian Cancer by using Sorafenib

1
Survival Improvements in Ovarian Cancer by
using Sorafenib
2
According to a new study, topotecan and Nexavar
(generic Sorafenib) when combined, and there
after used as a maintenance therapy has
significantly improve the survival outcomes in
women who are suffering from platinum-resistant
ovarian cancer.
3
According to a study, led by Radoslav Chekerov,
MD, of CharitéUniversitätsmedizin Berlin,
Germany, particularly poor prognosis was
represented in a population where the disease
relapses within 6 months of completing the
platinum therapy, which is classified as a
platinum-refractory or platinum-resistant ovarian
cancer. And data from previous researches has
proved that angiogenesis inhibition could be
effective in this setting.
4
A total of 174 women suffering from platinum
resistant ovarian cancer were recruited in the
new TRIAS trial. The patients were to receive
either placebo topotecan or sorafenib
topotecan. Among the 174 women, 85 were given
sorafenib topotecan and 89 were given placebo
topotecan. The completion of 6 cycles, patients
were to received either sorafenib or placebo for
next 1 year as a maintenance therapy.
5
Sorafenib/Nexavar Cost Information In the pool
of patients, characteristics of the patients in
the group were well balanced. Majority of the
patients has had an ECOG performance score of
either 0 or 1 and one or two prior chemotherapy
lines.
6
The mean progression free survival (PFS) for
sorafenib using patients was significantly higher
than placebo using patients. The median was 3.7
months for placebo group and almost double for
sorafenib group i.e. 6.7 months. After the
completion of chemotherapy sessions, 38 of
placebo group received a median of 1.4 months of
maintenance treatment as compared to 42 of
sorafenib group receiving a median of 1.6 months
of maintenance treatment.
7
The authors of the study believed that PFS is a
very meaning full outcome as most of the death
that occurred during the trial was due to the
fact that the disease was progressing. Due to
the use of sorafenib, the overall survival has
also improved. Placebo group had a median overall
survival of 10.1 months as compared to 17.1
months of overall survival in sorafenib group.
8
With the help of multivariate analysis, it was
observed that sorafenib treatment and
International Federation of Gynaecology (FIGO)
stage were the main forecaster of Progression
free survival (PFS), and in case of Overall
survival (OS), the main forecasters were
sorafenib treatment, FIGO stage and patients age.
9
The frequency of serious hostile events was
similar for both sorafenib and placebo group with
51 in placebo and 59 in sorafenib. Most
common hostile events were abdominal pain (10 in
sorafenib and 5 in placebo), neutropenia (7 in
sorafenib and 3 in placebo) and, dyspnea (7 in
sorafenib and 4 in placebo).
10
Grade 3 events like hand-foot skin reaction,
Leukopenia, and other dermatologic symptoms were
more likely to occur in sorafenib group than the
placebo group. According to Radoslav Chekerov,
TRIAS study is the only study that proves
improvement in both Progression free survival and
Overall survival for platinum ovarian cancer
patients. Above findings can further support
for the effect of antiangiogenic agents in
ovarian cancer and further investigation into
platinum-resistant ovarian cancer.
11
The only strength available for Nexavar is
Nexavar 200 mg. Sorafenib Cost Information The
information provided on the page is meant for the
purpose of being helpful and educational. It
should not be considered as medical
advice.   Sorafenib, nexavar, nexavar 200 mg,
nexavar cost, sorafenib cost, sorafenib mechanism
of action, nexavar 200, sorafenib dose
12
Contact Us Website www.CancerCurePharmacy.com E
mail CustomerCare_at_CancerCurePharmacy.com